TY  - GEN
AU  - Di Leo,A
AU  - Larsimont,D
AU  - Gancberg,D
AU  - Jarvinen,T
AU  - Beauduin,M
AU  - Vindevoghel,A
AU  - Michel,J
AU  - Focan,C H
AU  - Ries,F
AU  - Gobert,P H
AU  - Closon-Dejardin,M T
AU  - Dolci,S
AU  - Rouas,G
AU  - Paesmans,M
AU  - Lobelle,J P
AU  - Isola,J
AU  - Piccart,M J
TI  - HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide
SN  - 0923-7534
PY  - 2002///0221
KW  - Adult
KW  - Aged
KW  - Antigens, Neoplasm
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - administration & dosage
KW  - Biomarkers, Tumor
KW  - analysis
KW  - Breast Neoplasms
KW  - chemistry
KW  - Chemotherapy, Adjuvant
KW  - Confidence Intervals
KW  - Cyclophosphamide
KW  - DNA Topoisomerases, Type II
KW  - DNA-Binding Proteins
KW  - Epirubicin
KW  - Female
KW  - Fluorouracil
KW  - Genes, erbB-2
KW  - genetics
KW  - Humans
KW  - Methotrexate
KW  - Middle Aged
KW  - Predictive Value of Tests
KW  - Prognosis
KW  - Receptor, ErbB-2
KW  - Retrospective Studies
KW  - Treatment Outcome
N1  - Publication Type: Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1023/a:1011669223035
ER  -